EyePoint Pharmaceuticals, Inc.

NasdaqGM:EYPT Stock Report

Market Cap: US$609.0m

EyePoint Pharmaceuticals Management

Management criteria checks 3/4

EyePoint Pharmaceuticals' CEO is Jay Duker, appointed in Jan 2023, has a tenure of 1.5 years. total yearly compensation is $2.92M, comprised of 21.1% salary and 78.9% bonuses, including company stock and options. directly owns 0.086% of the company’s shares, worth $525.38K. The average tenure of the management team and the board of directors is 2.4 years and 3.4 years respectively.

Key information

Jay Duker

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage21.1%
CEO tenure2yrs
CEO ownership0.09%
Management average tenure2.4yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk

Dec 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

Oct 29
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

Sep 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Aug 15
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14
Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

CEO Compensation Analysis

How has Jay Duker's remuneration changed compared to EyePoint Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$79m

Dec 31 2023US$3mUS$614k

-US$71m

Sep 30 2023n/an/a

-US$100m

Jun 30 2023n/an/a

-US$106m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$2mUS$515k

-US$102m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$269k

-US$58m

Sep 30 2021n/an/a

-US$54m

Jun 30 2021n/an/a

-US$42m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$53kn/a

-US$45m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$52m

Mar 31 2020n/an/a

-US$51m

Dec 31 2019US$80kn/a

-US$57m

Sep 30 2019n/an/a

-US$58m

Jun 30 2019n/an/a

-US$75m

Mar 31 2019n/an/a

-US$98m

Dec 31 2018US$27kn/a

-US$86m

Compensation vs Market: Jay's total compensation ($USD2.92M) is about average for companies of similar size in the US market ($USD3.21M).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.

CEO

Jay Duker (65 yo)

2yrs

Tenure

US$2,915,146

Compensation

Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...

Leadership Team

NamePositionTenureCompensationOwnership
Jay Duker
President2yrsUS$2.92m0.086%
$ 525.4k
George Elston
Executive VP & CFO5.2yrsUS$1.78m0.068%
$ 412.1k
Ron Honig
Chief Legal Officer & Company Secretary6.2yrsno datano data
Jennifer Leonard
Chief People Officer & Senior VP of IT6yrsno datano data
David Jones
Senior VP & Chief Commercial Officer5.6yrsUS$1.46mno data
Michael Pine
Chief Business Officer1.3yrsUS$1.61m0.019%
$ 118.6k
Isabelle Lefebvre
Chief Regulatory Officer2.8yrsno datano data
Michael Maciocio
Chief Manufacturing Officerless than a yearno datano data
Marcia Sellos-Moura
Senior VP and Head of Development & Program Management1.5yrsno datano data
Ramiro Ribeiro
Chief Medical Officerless than a yearno datano data
Anna Kluczewska
CEO of AION Diagnostics Ltdno dataUS$225.94kno data

2.4yrs

Average Tenure

57yo

Average Age

Experienced Management: EYPT's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jay Duker
President1.5yrsUS$2.92m0.086%
$ 525.4k
Anna Kluczewska
CEO of AION Diagnostics Ltdno dataUS$225.94kno data
Goran Ando
Independent Non-Executive Chairman6.6yrsUS$214.78k0.019%
$ 114.1k
Wendy DiCicco
Independent Director5.5yrsUS$171.67k0.014%
$ 86.5k
Nancy Lurker
Vice Chair8.3yrsUS$3.74m0.32%
$ 1.9m
Carl Regillo
Co- Chairman of Scientific Advisory Board3.4yrsno datano data
Glenn Jaffe
Member of Executive Scientific Advisory Board3.4yrsno datano data
John Landis
Director6.3yrsUS$161.67k0.016%
$ 99.0k
Karen Zaderej
Independent Director2.5yrsUS$149.17k0.024%
$ 143.2k
Charles Wykoff
Co-Chair of Scientific Advisory Board3.4yrsno datano data
Rishi Singh
Member of Executive Scientific Advisory Board3.4yrsno datano data
Sophie Bakri
Member of Executive Scientific Advisory Board3.4yrsno datano data

3.4yrs

Average Tenure

66yo

Average Age

Experienced Board: EYPT's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 02:00
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EyePoint Pharmaceuticals, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Andrew D'SilvaB. Riley Securities, Inc.
Jennifer KimCantor Fitzgerald & Co.